MGNX
HEALTHCAREMacrogenics Inc
$3.01-0.14 (-4.44%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving MGNX Today?
No stock-specific AI insight has been generated for MGNX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.19$3.88
$3.01
Fundamentals
Market Cap$191M
P/E Ratio—
EPS$-1.18
Dividend Yield—
Dividend / Share—
ROE-0.9%
Profit Margin-0.5%
Debt / Equity—
Trading
Volume1.2M
Avg Volume (10D)—
Shares Outstanding63.6M
MGNX News
20 articles- Will MacroGenics (MGNX) Report Negative Q1 Earnings? What You Should KnowYahoo Finance·May 5, 2026
- MacroGenics and Sagard Healthcare Partners Enter into Expanded ZYNYZ® Royalty Purchase AgreementYahoo Finance·May 4, 2026
- SNY's Tzield Gets FDA Nod for Kids, Sarclisa SC BLA Faces DelayYahoo Finance·Apr 23, 2026
- B. Riley Sees Upside in MacroGenics, Inc. (MGNX) Following Gilead-Driven Sector ActivityYahoo Finance·Apr 17, 2026
- FDA Removes Partial Clinical Hold on MacroGenics’ LINNET StudyYahoo Finance·Apr 8, 2026
- April 2026's Most Promising Penny StocksYahoo Finance·Apr 8, 2026
- MacroGenics (MGNX) Reports Q4 Loss, Tops Revenue EstimatesYahoo Finance·Mar 9, 2026
- MacroGenics: Q4 Earnings SnapshotYahoo Finance·Mar 9, 2026
- MacroGenics Reports 2025 Financial Results and Highlights Upcoming Planned Data DisclosuresYahoo Finance·Mar 9, 2026
- BioLife Solutions, Inc. (BLFS) Surpasses Q4 Earnings and Revenue EstimatesYahoo Finance·Feb 26, 2026
- MacroGenics to Participate in Upcoming Investor ConferencesYahoo Finance·Feb 26, 2026
- MacroGenics Announces Pausing of Enrollment of New Study Participants in LINNET TrialYahoo Finance·Feb 23, 2026
- January 2026's Top Penny Stocks To WatchYahoo Finance·Jan 27, 2026
- [Latest] Global T-Cell Engagers Market Size/Share Worth USD 18.8 Billion by 2034 at a 21.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)Yahoo Finance·Jan 14, 2026
- Sanofi's Teizeild Gets EU Approval for Treating Type 1 DiabetesYahoo Finance·Jan 13, 2026
- FDA Accepts SNY Filing for Expanded Use of T1D Drug in Young ChildrenYahoo Finance·Jan 5, 2026
- December 2025 Penny Stocks Worth WatchingYahoo Finance·Dec 18, 2025
- MacroGenics to Participate in the 8th Annual Evercore Healthcare ConferenceYahoo Finance·Nov 25, 2025
- Results: MacroGenics, Inc. Confounded Analyst Expectations With A Surprise ProfitYahoo Finance·Nov 15, 2025
- MacroGenics (MGNX) Q3 Earnings and Revenues Surpass EstimatesYahoo Finance·Nov 12, 2025
All 20 articles loaded
Price Data
Open$3.20
Previous Close$3.15
Day High$3.30
Day Low$3.10
52 Week High$3.88
52 Week Low$1.19
52-Week Range
$1.19$3.88
$3.01
Fundamentals
Market Cap$191M
P/E Ratio—
EPS$-1.18
Dividend Yield—
Dividend / Share—
ROE-0.9%
Profit Margin-0.5%
Debt / Equity—
Trading
Volume1.2M
Avg Volume (10D)—
Shares Outstanding63.6M
About Macrogenics Inc
MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapies to treat cancer in the United States. The company is headquartered in Rockville, Maryland.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—